Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present PharmaRoth Labs, Inc. (OTC: ROTH).

Full DD Report for ROTH

You must become a subscriber to view this report.


Recent News from (OTC: ROTH)

Budgeting, Savings, Investing, And Retirement Planning
Retirement planning is not just setting goals for savings and investing. Sure, they are an important part of it. But we believe it starts with budgeting, which is a critical part of retirement planning. Without budgeting, there would not be much of savings unless your income is limitless. We t...
Source: SeekingAlpha
Date: March, 03 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.00180.001860.001860.0018500,400
2018-12-130.00150.00150.00150.001530,000
2018-12-120.00150.00150.00150.0015132,000
2018-12-110.00150.00150.00150.0015140,000
2018-12-100.00160.00190.00190.0015157,304

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14500,000500,40099.9201Short
2018-12-1075,000157,30447.6784Short
2018-12-04460,5001,195,73638.5118Short
2018-12-031,343,2922,160,00062.1894Short
2018-11-28161,211161,211100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ROTH.


About PharmaRoth Labs, Inc. (OTC: ROTH)

Logo for PharmaRoth Labs, Inc. (OTC: ROTH)

PharmaRoth Labs, Inc. is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world wide rights related to the production, marketing, and distribution of Sucanon R , an oral treatment for Type II diabetes. Sucanon R is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth s strategy is to increase awareness, acceptance, and distribution of Sucanon R globally.

 

Contact Information

 

 

Current Management

  • Luis Manuel Ornelas Lopez / President, CEO, COO
  • Barry Hall / Interim CFO

Current Share Structure

  • Market Cap: $1,299,372 - 03/21/2018
  • Authorized: 500,000,000 - 05/10/2017
  • Issue and Outstanding: 351,181,637 - 05/10/2017
  • Float: 200,116,667 - 05/11/2017

 


Recent Filings from (OTC: ROTH)

Notification of Late Filing - Pharmaroth Labs Quarterly Report
Filing Type: Notification of Late Filing - Pharmaroth Labs Quarterly ReportFiling Source: OTC Markets
Filing Date: February, 14 2018
Attorney Letter with Respect to Current Information - Pharmaroth Labs, Inc. Legal Opinion Letter
Filing Type: Attorney Letter with Respect to Current Information - Pharmaroth Labs, Inc. Legal Opinion LetterFiling Source: OTC Markets
Filing Date: November, 29 2017
Quarterly Report - Pharmaroth Labs Quarterly Report - September 30, 2017 (Unaudited)
Filing Type: Quarterly Report - Pharmaroth Labs Quarterly Report - September 30, 2017 (Unaudited)Filing Source: OTC Markets
Filing Date: November, 21 2017
Notification of Late Filing - Pharmaroth Labs Quarterly Report
Filing Type: Notification of Late Filing - Pharmaroth Labs Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 14 2017
Annual Report - Pharmaroth Labs Annual Report - June 30, 2017 (Unaudited)
Filing Type: Annual Report - Pharmaroth Labs Annual Report - June 30, 2017 (Unaudited)Filing Source: OTC Markets
Filing Date: October, 19 2017
Supplemental Information - Pharmaroth Labs, Inc. Issuer Information and Disclosre Statement - October 13, 2017
Filing Type: Supplemental Information - Pharmaroth Labs, Inc. Issuer Information and Disclosre Statement - OctobeFiling Source: OTC Markets
Filing Date: October, 13 2017
Notification of Late Filing - Pharmaroth Labs Annual Report
Filing Type: Notification of Late Filing - Pharmaroth Labs Annual ReportFiling Source: OTC Markets
Filing Date: September, 29 2017

 

 


Daily Technical Chart for (OTC: ROTH)

Daily Technical Chart for (OTC: ROTH)


Stay tuned for daily updates and more on (OTC: ROTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ROTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ROTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ROTH and does not buy, sell, or trade any shares of ROTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/